Soleno Therapeutics (NASDAQ:SLNO) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Monday, ValuEngine reports.

Separately, Zacks Investment Research raised Soleno Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Saturday, March 16th.

Shares of NASDAQ:SLNO opened at $2.60 on Monday. Soleno Therapeutics has a 1-year low of $1.11 and a 1-year high of $5.07. The firm has a market cap of $82.62 million, a price-to-earnings ratio of -4.00 and a beta of 2.49. The stock’s 50 day moving average price is $2.44.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.07. Sell-side analysts anticipate that Soleno Therapeutics will post -0.77 EPS for the current fiscal year.

In other news, major shareholder Bioasia Mangement Llc sold 90,724 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $1.93, for a total transaction of $175,097.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 43.27% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLNO. Virtu Financial LLC acquired a new stake in Soleno Therapeutics during the 1st quarter worth about $72,000. Trellus Management Company LLC grew its stake in shares of Soleno Therapeutics by 42.1% in the 1st quarter. Trellus Management Company LLC now owns 240,645 shares of the company’s stock valued at $496,000 after buying an additional 71,265 shares during the period. Finally, Fosun International Ltd grew its stake in shares of Soleno Therapeutics by 4.7% in the 1st quarter. Fosun International Ltd now owns 188,982 shares of the company’s stock valued at $397,000 after buying an additional 8,569 shares during the period. Hedge funds and other institutional investors own 46.08% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.

Featured Article: What is a portfolio manager?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with's FREE daily email newsletter.